Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer

Abstract

The age-specific of occurrence of cervical cancer related to human papillomavirus genotypes HPV16 and HPV18, the two targeted by current HPV vaccines, is not well described. We therefore used data from two large, tissue-based HPV genotyping studies of cervical cancer, one conducted in New Mexico (USA) (n = 744) and an international study restricted to cancers (n = 1,729) from Europe, North America, and Australia to represent those regions with widely available cervical cancer screening facilities. HPV results were categorized as HPV16 or HPV18 positive (HPV16/18) versus other HPV genotype. We observed a decreasing proportion of HPV16/18-positive cancers with increasing age in the international study (ptrend < 0.001) and New Mexico study (ptrend < 0.001). There was no heterogeneity in the relationship between age of diagnosis and the proportion of HPV16/18-positive cancers between studies (p = 0.8). Combining results from the two studies (n = 2,473), the percentages of HPV16/18-positive cases were 77.0% (95%CI: 75.1%-78.9%) for women less than 65 years old and 62.7% (95%CI: 58.4%-66.9%) for women aged 65 and older (p < 0.001). In women who are under the age of 25 and have been vaccinated before becoming sexually active, the cervical cancer incidence is expected to be approximately 3.5 per million by 2020. HPV vaccination against HPV16/18 may have a greater impact on cervical cancers in women under 65 than in women aged 65 and older. These data will inform the age-specific impact of HPV vaccination and its integration with cervical cancer screening activities.

Cervical Pathology in High-Risk Human Papillomavirus-Positive, Cytologically Normal Women

“…This finding was in line with previous study which noted that the majority of cervical cancer observed among women below 35 years caused by HPV 16/18 (de Sanjose et al, 2013).…”

“…Infection of high-risk human papillomavirus (HR-HPV) is a cause of cervical cancer (Suthipintawong et al, 2011;Siriaunkgul et al, 2012;de Sanjose et al, 2013;Sui et al, 2013;Natphopsuk et al, 2013;Hamzi Abdul Raub et al, 2014). This has led to incorporate HR-HPV testing into cytology screening methods, the so-called "cotests".…”

Age and Survival of Cervical Cancer Patients with Bone Metastasis

“…The majority of the patients (89-92%) were aged under 45 ,who had HPV 16/18 infected tumors, which were more than the older patients (73-78%), (Carozzi et al, 2010). This is consistent with an international study which observed a decreasing proportion of HPV16/18-positive cancers with increasing age, (de Sanjose et al, 2013). In 10.2% of invasive cancers, in which coinfections were observed, HPV 16 was involved in the highest rate of coinfections along with other HPV types (77%), (Carozzi et al, 2010).…”

Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions

“…The lower contribution of the nine HPV types by age is mainly due to the lower contribution of HPV16. HPV16 related tumors, but also HPV18 and 45, are more aggressive and cause tumors or precancerous lesions that are detected at an earlier age, while some other carcinogenic HPV genotypes might develop tumours at later ages [32]. Although in our study, overall RC decreased with age in all female anogenital cancers, the low number of cases included for anogenital sites other than cervix can lead to instability in the estimates.…”